RT Journal Article
SR Electronic
T1 Using the illness-death model to estimate age- and sex-standardized incidence rates of diabetes in Mexico from 2003 to 2015
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.27.23300547
DO 10.1101/2023.12.27.23300547
A1 Silverman-Retana, Omar
A1 Brinks, Ralph
A1 Hoyer, Annika
A1 Witte, Daniel R.
A1 Tönnies, Thaddäus
YR 2023
UL http://medrxiv.org/content/early/2023/12/29/2023.12.27.23300547.abstract
AB Objectives To estimate the age-specific and age-standardized incidence rate of diabetes for men and women in Mexico between 2003 and 2015, and to assess the relative change in incidence of diabetes between 2003 and 2015.Methods We use a partial differential equation describing the illness-death model to estimate the incidence rate (IR) of diabetes for the years 2003, 2009 and 2015 based on prevalence data from National Health Surveys conducted in Mexico, the mortality rate of the Mexican general population and plausible input values for age-specific mortality rate ratios associated with diabetes.Results The age-standardized IR of diabetes per 1000 person years (pryr) was similar among men (IRm) and women (IRw) in the year 2003 (IRm 6.1 vs. IRw 6.5 1000/pryr), 2009 (IRm: 7.0 vs. IRw: 8.4 1000/pryr), and in 2015 (IRm 8.0 vs. IRw 10.6 1000/pryr).Conclusions The incidence rate of diabetes in Mexico between the years 2003 and 2015 remained stable. However, rates were markedly higher among women in the age group 40-49 and 50-59 in the year 2015 compared with rates in 2003.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used publicly available data. ENSANUT data can be accessed here: https://ensanut.insp.mx/. Vital statistics data and census data can be accessed here: https://www.inegi.org.mx/datosabiertos/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe used publicly available data. ENSANUT data can be accessed here: https://ensanut.insp.mx/. Vital statistics data and census data can be accessed here: https://www.inegi.org.mx/datosabiertos/ https://ensanut.insp.mx/ https://www.inegi.org.mx/datosabiertos/